drugset / Trial / NCT00918177

An Evaluation of the Pharmacokinetics and Pharmacodynamics of AP09004 in Patients With Parkinson's Disease

NCT00918177

Phase 2 Completed 72 enrolled Intec Pharma Ltd.
RandomizedCrossoverOpen-labelTreatment

Summary

The purpose of this study is to evaluate blood level profiles of multiple oral doses of AP09004 vs. active control and to determine its safety and efficacy in Parkinson's patients.

Timeline

Start
2009-07
Primary completion
2012-10
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject AP09004 Unknown Oral
Subject Carbidopa Unknown
Subject Levodopa Small molecule

Indications